Salarius Pharmaceuticals, Inc. - Common Stock (SLRX)

The Viral Threat Hiding in Plain Sight: Between August 2024 and July 2025, the CDC’s NoroSTAT system recorded 2,675 norovirus outbreaks across the United States. A genetic shift has emerged: the GII.17 strain has overtaken the long-dominant GII.4 lineage , now responsible for roughly 75 percent of reported cases . Health officials warn this strain replacement increases outbreak frequency and severity, as current cleaning and immunity defenses are quickly becoming outdated. Why It Matters

Nika Pharmaceuticals, Inc. (OTCQB: NIKA ), a next-generation biopharmaceutical company focused on immune-strengthening therapeutics, is emerging as a compelling investment opportunity in the global fight against HIV/AIDS, Hepatitis B and C, Rheumatoid Arthritis, Cancer, and Diabetes . With a robust pipeline of proprietary drugs and supplements designed to enhance cellular immunity, NIKA is positioned to address multi-billion-dollar markets in both pharmaceuticals and nutraceuticals .

Specificity Inc. (OTCID: SPTY), a next-generation digital marketing firm, has regained its status as a fully reporting SEC current filer—marking a key milestone as it continues to revolutionize audience targeting across digital platforms. Known for eliminating bots and irrelevant impressions, Specificity’s proprietary ad tech delivers precision-targeted ads across display, social, and Connected TV (CTV) to the same verified, high-intent audiences —maximizing ROI and minimizing waste.

Power Metallic Mines Inc. (TSXV: PNPN, OTCQB: PNPNF ) has reached a historic milestone by securing the largest exploration license in Saudi Arabia’s Jabal Sayid Belt , marking a major step in the company’s global expansion strategy. The awarded Jabal Baudan project spans over 200 square kilometers , targeting copper, gold, and zinc in one of the Kingdom’s most mineral-rich regions.

Ademi LLP is investigating Salarius (NASDAQ: SLRX) for possible breaches of fiduciary duty and other violations of law in its transaction with Decoy Therapeutics.